In:
Clinical Nuclear Medicine, Ovid Technologies (Wolters Kluwer Health), Vol. 48, No. 3 ( 2023-3), p. 228-232
Kurzfassung:
Invasive lobular breast cancer (ILC) may be hard to detect using conventional imaging modalities and usually shows less avidity to 18 F-FDG PET/CT. 68 Ga–fibroblast activation protein inhibitor (FAPI) PET/CT has shown promising results in detecting non– 18 F-FDG–avid cancers. We aimed to assess the feasibility of detecting metastatic disease in patients with non– 18 F-FDG–avid ILC. Methods This prospective study included patients with metastatic ILC, infiltrative to soft tissues, which was not 18 F-FDG avid. The patients underwent 68 Ga-FAPI PET/CT for evaluation, which was correlated with the fully diagnostic CT performed at the same time. Results Seven women (aged 57 ± 10 years) were included. Among the 30 organs and structures found to be involved by tumor, the number of findings observed by FAPI PET/CT was significantly higher than that observed by CT alone ( P = 0.022), especially in infiltrative soft tissue and serosal locations. Conclusions This small pilot trial suggests a role for 68 Ga-FAPI PET/CT in ILC, which needs to be confirmed by subsequent trials.
Materialart:
Online-Ressource
ISSN:
1536-0229
,
0363-9762
DOI:
10.1097/RLU.0000000000004540
Sprache:
Englisch
Verlag:
Ovid Technologies (Wolters Kluwer Health)
Publikationsdatum:
2023
ZDB Id:
2045053-9
Permalink